Valuation: Omeros Corporation

Market Cap 709M 623M 580M 533M 1B 67.95B 1.01B 6.89B 2.69B 33.55B 2.66B 2.6B 116B P/E 2026 *
-163x
P/E 2027 * 128x
Enterprise Value 709M 623M 580M 533M 1B 67.95B 1.01B 6.89B 2.69B 33.55B 2.66B 2.6B 116B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 4.95x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day+15.83%
1 week+17.76%
Current month+19.24%
1 month+14.43%
3 months-23.07%
6 months-10.50%
Current year-33.97%
1 week 9.34
Extreme 9.3415
11.65
1 month 8.52
Extreme 8.517
11.65
Current year 6.7
Extreme 6.7023
17.63
1 year 3.44
Extreme 3.435
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 15/06/1994
Director of Finance/CFO 62 29/06/2024
Chief Tech/Sci/R&D Officer 70 31/10/2019
Director TitleAgeSince
Chairman 67 15/06/1994
Director/Board Member 86 31/12/1994
Director/Board Member 72 31/12/1994
Date Insider Type Main position Quantity % Market Cap.
22/07/26 Free

General Counsel

105,000 0.1451%
22/07/26 Free

Chief Financial Officer

105,000 0.1451%
22/07/26 Free

Chief Executive Officer

1,000,000 1.3817%
Change 5-day change 1-year change 3-year change Capi.($)
+15.83%+17.76%+173.25%+160.69% 709M
-1.82%+5.03%+56.71%+66.69% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-2.05%-2.14%+2.93%+413.38% 23.18B
+1.97%-1.16%-19.24%-13.25% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+2.09%+28.01%-27.56% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+0.79%+0.50%+25.73%+184.74% 13.92B
Average +2.08%+1.56%+55.41%+175.46% 24.08B
Weighted average by Cap. -0.01%+1.93%+40.76%+137.91%

Financials

2026 *2027 *
Net sales 67.83M 59.63M 55.51M 50.98M 95.73M 6.51B 96.99M 660M 258M 3.21B 255M 249M 11.1B 143M 126M 117M 108M 202M 13.72B 205M 1.39B 544M 6.78B 537M 526M 23.42B
Net income -12.1M -10.64M -9.9M -9.09M -17.08M -1.16B -17.3M -118M -45.97M -573M -45.42M -44.44M -1.98B 1.25M 1.1M 1.02M 939K 1.76M 120M 1.79M 12.16M 4.75M 59.19M 4.69M 4.59M 205M
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
27/07/26 US$11.34 +15.83% 3,356,932
24/07/26 US$9.790 -4.77% 799,038
23/07/26 US$10.28 +4.47% 1,544,963
22/07/26 US$9.840 +3.25% 1,229,960
21/07/26 US$9.530 -1.04% 1,019,774
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
9.790USD
Average target price
33.00USD
Spread / Average Target
+237.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock